Magazine Article | March 1, 2023

Outsourcing Strategies For Maximizing Drug Exclusivity

Source: Life Science Leader

By John Serio and Christopher Head

It is extremely important when outsourcing projects to a CDMO that contractual agreements clearly spell out ownership of discoveries and data uncovered during the outsourced development process.

From an IP perspective, an overarching theme common throughout the use of these organizations is the importance of capturing and protecting all points of novelty associated with a drug’s chemistry, manufacturing, and controls (CMC). Frequently, during the CMC development period, novel compositions, processes, and conditions may be discovered that may be used to extend the product’s life cycle.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader